205 related articles for article (PubMed ID: 23202523)
1. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults.
Chichester JA; Jones RM; Green BJ; Stow M; Miao F; Moonsammy G; Streatfield SJ; Yusibov V
Viruses; 2012 Nov; 4(11):3227-44. PubMed ID: 23202523
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults.
Cummings JF; Guerrero ML; Moon JE; Waterman P; Nielsen RK; Jefferson S; Gross FL; Hancock K; Katz JM; Yusibov V;
Vaccine; 2014 Apr; 32(19):2251-9. PubMed ID: 24126211
[TBL] [Abstract][Full Text] [Related]
3. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
6. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza.
Landry N; Ward BJ; Trépanier S; Montomoli E; Dargis M; Lapini G; Vézina LP
PLoS One; 2010 Dec; 5(12):e15559. PubMed ID: 21203523
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
Schuind A; Segall N; Drame M; Innis BL
J Infect Dis; 2015 Aug; 212(4):531-41. PubMed ID: 25722291
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults.
Song JY; Choi MJ; Noh JY; Choi WS; Cheong HJ; Wie SH; Lee JS; Woo GJ; Lee SH; Kim WJ
Hum Vaccin Immunother; 2017 May; 13(5):1190-1197. PubMed ID: 27996363
[TBL] [Abstract][Full Text] [Related]
11. Clinical testing of an inactivated influenza A/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam.
Phan TL; Ho VT; Vu MH; Nguyen TN; Duong HT; Holt R; Wahid R; Donnelly J; Flores J
Vaccine; 2016 Oct; 34(45):5449-5456. PubMed ID: 27591953
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
14. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
15. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.
Nagai H; Ikematsu H; Tenjinbaru K; Maeda A; Dramé M; Roman FP
BMC Infect Dis; 2010 Nov; 10():338. PubMed ID: 21108818
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
Chanthavanich P; Anderson E; Kerdpanich P; Bulitta M; Kanesa-Thasan N; Hohenboken M
Pediatr Infect Dis J; 2019 Jul; 38(7):757-764. PubMed ID: 31194712
[TBL] [Abstract][Full Text] [Related]
17. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.
Feldman RA; Fuhr R; Smolenov I; Mick Ribeiro A; Panther L; Watson M; Senn JJ; Smith M; Almarsson Ӧ; Pujar HS; Laska ME; Thompson J; Zaks T; Ciaramella G
Vaccine; 2019 May; 37(25):3326-3334. PubMed ID: 31079849
[TBL] [Abstract][Full Text] [Related]
18. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.
Langley JM; Risi G; Caldwell M; Gilderman L; Berwald B; Fogarty C; Poling T; Riff D; Baron M; Frenette L; Sheldon E; Collins H; Shepard M; Dionne M; Brune D; Ferguson L; Vaughn D; Li P; Fries L
J Infect Dis; 2011 Jun; 203(12):1729-38. PubMed ID: 21606531
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study.
Kim JH; Drame M; Puthanakit T; Chiu NC; Supparatpinyo K; Huang LM; Chiu CH; Chen PY; Hwang KP; Danier J; Friel D; Salaun B; Woo W; Vaughn DW; Innis B; Schuind A
Pediatr Infect Dis J; 2021 Sep; 40(9):e333-e339. PubMed ID: 34285165
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.
Treanor JJ; Essink B; Hull S; Reed S; Izikson R; Patriarca P; Goldenthal KL; Kohberger R; Dunkle LM
Vaccine; 2013 Nov; 31(48):5760-5. PubMed ID: 24075920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
